Low incidence of severe bacterial infections in hospitalised patients with COVID-19: A population-based registry study

References

• Thakur V, Ratho RK, Kumar P, et al. Multi-organ involvement in covid-19: beyond pulmonary manifestations. JCM. 2021;10(3):446.
   Google Scholar
• Bakaletz LO. Viral–bacterial co-infections in the respiratory tract. Curr Opin Microbiol. 2017;35:30–35.
   PubMed Web of Science ®Google Scholar
• Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622–1629.
   PubMed Web of Science ®Google Scholar
• Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27(4):520–531.
   PubMed Web of Science ®Google Scholar
• Forsblom E, Silén S, Kortela E, et al. Male predominance in disease severity and mortality in a low covid-19 epidemic and low case-fatality area – a population-based registry study. Infect Dis (Lond). 2021;53(10):789–799.
   PubMed Web of Science ®Google Scholar
• Jokela P, Jääskeläinen AE, Jarva H, et al. SARS-CoV-2 sample-to-answer nucleic acid testing in a tertiary care emergency department: evaluation and utility. J Clin Virol. 2020;131:104614.
   PubMed Web of Science ®Google Scholar
• Mannonen L, Kallio-Kokko H, Loginov R, et al. Comparison of two commercial platforms and a Laboratory-Developed test for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA. J Mol Diagn. 2021;23(4):407–416.
   PubMed Web of Science ®Google Scholar
• Buetti N, Ruckly S, de Montmollin E, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case–cohort study from the multicentric OUTCOMEREA network. Intensive Care Med. 2021;47(2):180–187.
   PubMed Web of Science ®Google Scholar
• Cohen R, Finn T, Babushkin F, et al. High rate of bacterial respiratory tract co-infections upon admission amongst moderate to severe COVID-19 patients. Infect Dis. 2022;54(2):134–144.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27(1):83–88.
   PubMed Web of Science ®Google Scholar
• Ripa M, Galli L, Poli A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect. 2021;27(3):451–457.
   PubMed Web of Science ®Google Scholar
• Abani O, Abbas A, Abbas F, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, RECOVERY Collaborative Group, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384(8):693–704.,
   PubMed Web of Science ®Google Scholar
• Gragueb-Chatti I, Lopez A, Hamidi D, et al. Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study. Ann Intensive Care. 2021;11(1):87.
   PubMed Web of Science ®Google Scholar
• Pettit NN, Nguyen CT, Mutlu GM, et al. Late onset infectious complications and safety of tocilizumab in the management of COVID-19. J Med Virol. 2021;93(3):1459–1464.
   PubMed Web of Science ®Google Scholar
• Karami Z, Knoop BT, Dofferhoff ASM, et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis. 2021;53(2):102–110.
   PubMed Web of Science ®Google Scholar
• Hughes S, Troise O, Donaldson H, et al. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26(10):1395–1399.
   PubMed Web of Science ®Google Scholar
• Grasselli G, Scaravilli V, Mangioni D, et al. Hospital-acquired infections in critically ill patients with COVID-19. Chest. 2021;160(2):454–465.
   PubMed Web of Science ®Google Scholar
• Surveillance of Antimicrobial Resistance in Europe. 2020. Data. Executive Summary
   Google Scholar
• Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020;9(1):1–7.
   PubMed Web of Science ®Google Scholar
• Alanio A, Dellière S, Fodil S, et al. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8(6):e48–e49.
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: a prospective study. Clin Infect Dis. 2021;73(11):3606–3620.
   Web of Science ®Google Scholar
• Strausz S, Kiiskinen T, Broberg M, FinnGen, et al. Sleep apnoea is a risk factor for severe COVID-19. BMJ Open Resp Res. 2021;8(1):e000845.
   PubMed Web of Science ®Google Scholar
• Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York city pandemic surge. Infect Control Hosp Epidemiol. 2021;42(1):84–88.
   PubMed Web of Science ®Google Scholar
• Vaughn VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clin Infect Dis. 2021;72(10):e533–e541.
   PubMed Web of Science ®Google Scholar